Page last updated: 2024-08-05 12:21:57
L-valine derivative
A proteinogenic amino acid derivative resulting from reaction of L-valine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-valine by a heteroatom.
ChEBI ID: 84129
Members (5)
| Member | Definition | Role |
|---|---|---|
| gs-5816 | A complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes. | velpatasvir |
| ledipasvir | A benzimidazole derivative that is used in combination with sofosbuvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection. | ledipasvir |
| mk-8742 | A complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults. | elbasvir |
| n-acetylvaline | An L-valine derivative in which one of the amino hydrogens of L-valine has been replaced by an acetyl group. | N-acetyl-L-valine |
| ritonavir | An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. | ritonavir |
Research
Studies (5,793)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (0.03) | 18.7374 |
| 1990's | 469 (8.10) | 18.2507 |
| 2000's | 1,661 (28.67) | 29.6817 |
| 2010's | 2,349 (40.55) | 24.3611 |
| 2020's | 1,312 (22.65) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,449 (23.43%) | 5.53% |
| Reviews | 546 (8.83%) | 6.00% |
| Case Studies | 600 (9.70%) | 4.05% |
| Observational | 159 (2.57%) | 0.25% |
| Other | 3,430 (55.47%) | 84.16% |